MCID: MNN020
MIFTS: 47

Meningococcal Infection

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningococcal Infection

MalaCards integrated aliases for Meningococcal Infection:

Name: Meningococcal Infection 53
Meningococcal Infections 43 73

Classifications:



External Ids:

ICD10 33 A39
UMLS 73 C0025303

Summaries for Meningococcal Infection

MedlinePlus : 43 Meningococci are a type of bacteria that cause serious infections. The most common infection is meningitis, which is an inflammation of the thin tissue that surrounds the brain and spinal cord. Meningococci can also cause other problems, including a serious bloodstream infection called sepsis. Meningococcal infections can spread from person to person. Risk factors include Age - it is more common in infants, teens, and young adults Living in close quarters, such as in college dorms or military settings Certain medical conditions, such as not having a spleen Travel to areas where meningococcal disease is common In its early stages, you may have flu-like symptoms and a stiff neck. But the disease can progress quickly and can be fatal. Early diagnosis and treatment are extremely important. Lab tests on your blood and cerebrospinal fluid can tell if you have it. Treatment is with antibiotics. Since the infection spreads from person to person, family members may also need to be treated. A vaccine can prevent meningococcal infections.

MalaCards based summary : Meningococcal Infection, also known as meningococcal infections, is related to aortic coarctation and myocardial infarction, and has symptoms including fever and pruritus. An important gene associated with Meningococcal Infection is C7 (Complement C7), and among its related pathways/superpathways are Aldosterone synthesis and secretion and G-protein signaling G-Protein alpha-i signaling cascades. The drugs Ciprofloxacin and Histidine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 76 Neisseria meningitidis, often referred to as meningococcus, is a Gram-negative bacterium that can cause... more...

Related Diseases for Meningococcal Infection

Diseases related to Meningococcal Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 aortic coarctation 29.4 ADRB1 ADRB2 AGT AGTR1
2 myocardial infarction 29.1 ADD1 ADRB1 ADRB2 AGT AGTR1
3 neisseria meningitidis infection 11.8
4 waterhouse-friderichsen syndrome 11.6
5 meningitis 11.4
6 properdin deficiency, x-linked 11.4
7 complement factor h deficiency 11.1
8 meningococcal meningitis 10.3
9 disseminated intravascular coagulation 10.2
10 lymphosarcoma 10.1 G6PD GSR
11 congenital methemoglobinemia 10.1 G6PD SOD1
12 pediatric hypertension 10.1 ADD1 AGT
13 renal artery disease 10.1 AGT AGTR1
14 posterior urethral valves 10.1 AGT AGTR1
15 microvascular complications of diabetes 3 10.1 AGT AGTR1
16 anuria 10.1 AGT AGTR1
17 malignant hypertension 10.1 AGT AGTR1
18 resting heart rate, variation in 10.1 ADRB1 ADRB2
19 ocular hypotension 10.1 ADRB1 ADRB2
20 diastolic heart failure 10.1 AGT AGTR1
21 complement deficiency 10.1
22 fibromuscular dysplasia 10.1 AGT AGTR1
23 renal tubular dysgenesis 10.1 AGT AGTR1
24 myocardial stunning 10.0 AGTR1 SOD1
25 ischemic optic neuropathy 10.0 AGT AGTR1 G6PD
26 familial hypertension 10.0 AGT AGTR1
27 senile cataract 10.0 G6PD GSR SOD1
28 pericarditis 10.0
29 acute mountain sickness 10.0 ADRB2 AGTR1
30 orthostatic intolerance 10.0 ADRB1 ADRB2 AGTR1
31 nephrosclerosis 9.9 ADRB1 AGTR1
32 coronary artery anomaly 9.9 ADRB1 ADRB2 AGTR1
33 congestive heart failure 9.9 ADRB1 ADRB2 AGTR1
34 malaria 9.9
35 arthritis 9.9
36 hepatitis 9.9
37 septic arthritis 9.9
38 myocarditis 9.9
39 bacterial meningitis 9.9
40 meningococcemia 9.9
41 properdin deficiency 9.9
42 atrial fibrillation 9.9 ADRB1 AGT AGTR1
43 hypertensive heart disease 9.9 AGT AGTR1
44 retinitis pigmentosa 7 9.8 ROM1 TTR
45 systemic lupus erythematosus 9.8
46 complement component 5 deficiency 9.8
47 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
48 hepatitis b 9.8
49 thrombocytopenia 9.8
50 rabies 9.8

Graphical network of the top 20 diseases related to Meningococcal Infection:



Diseases related to Meningococcal Infection

Symptoms & Phenotypes for Meningococcal Infection

UMLS symptoms related to Meningococcal Infection:


fever, pruritus

MGI Mouse Phenotypes related to Meningococcal Infection:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.81 ADRB1 ADRB2 AGT AGTR1 G6PD GSR
2 growth/size/body region MP:0005378 9.56 ADD1 ADRB1 ADRB2 AGT AGTR1 CPB2
3 homeostasis/metabolism MP:0005376 9.28 ADD1 ADRB1 ADRB2 AGT AGTR1 CPB2

Drugs & Therapeutics for Meningococcal Infection

Drugs for Meningococcal Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
2
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
3
Lactitol Investigational Phase 4,Phase 3,Phase 2,Not Applicable 585-86-4 3871
4 Complement Factor H Phase 4
5 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antibodies Phase 4,Phase 3,Phase 2,Not Applicable
8 Immunoglobulins Phase 4,Phase 3,Phase 2,Not Applicable
9 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
10 Laxatives Phase 4,Phase 3,Phase 2,Not Applicable
11 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Cathartics Phase 4,Phase 3,Phase 2,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Not Applicable
14 Anti-Infective Agents Phase 4,Phase 3
15 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
16 Topoisomerase Inhibitors Phase 4
17 Cytochrome P-450 Enzyme Inhibitors Phase 4
18
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 11953898 44475014
19
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
20
Acetaminophen Approved Phase 3 103-90-2 1983
21
Edetic Acid Approved, Vet_approved Phase 3,Phase 2 62-33-9, 60-00-4 6049
22
Iron Approved Phase 3,Phase 2 7439-89-6 23925
23
Pentetic acid Approved Phase 3,Phase 2 67-43-6
24
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3,Phase 1 21645-51-2
25
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
26
Cobalamin Experimental Phase 3,Phase 2 13408-78-1 6438156
27 Vitamin B 12 Phase 3,Phase 2
28 Vitamin B12 Phase 3,Phase 2
29 Complement System Proteins Phase 3
30 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
31 Analgesics, Non-Narcotic Phase 3
32 Antipyretics Phase 3,Phase 2
33 Analgesics Phase 3
34 Peripheral Nervous System Agents Phase 3
35 Antidotes Phase 3,Phase 2
36 PENTA Phase 3,Phase 2
37 Fibrinolytic Agents Phase 3
38 Anticoagulants Phase 3
39 Chelating Agents Phase 3,Phase 2
40 Iron Chelating Agents Phase 3,Phase 2
41 Protective Agents Phase 3,Phase 2
42 Anti-Ulcer Agents Phase 2, Phase 3,Phase 1
43 Antacids Phase 2, Phase 3,Phase 1
44 Adjuvants, Immunologic Phase 2, Phase 3,Phase 1
45
Aluminum sulfate Approved Phase 2 10043-01-3
46 Antibodies, Monoclonal Phase 2
47 Hops Approved Phase 1
48
Salmon Calcitonin Approved, Investigational 47931-85-1 16129616
49
Calcitonin gene-related peptide Investigational 83652-28-2
50 Bone Density Conservation Agents

Interventional clinical trials:

(show top 50) (show all 260)
# Name Status NCT ID Phase Drugs
1 Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Unknown status NCT02569632 Phase 4
2 Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine Unknown status NCT00262015 Phase 4
3 Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age Completed NCT00310635 Phase 4
4 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
5 Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Completed NCT00850603 Phase 4
6 Persistence of Antibody Response to N. Meningitidis Group C in Children Completed NCT00316654 Phase 4
7 Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine Completed NCT00310713 Phase 4
8 Kinetics of B Cell Response in Infants Menjugate Vaccination Completed NCT00310700 Phase 4
9 Persistence of Immune Response After Vaccination With MCC Completed NCT00310687 Phase 4
10 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed NCT01270503 Phase 4
11 Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations Completed NCT02446691 Phase 4
12 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed NCT01823536 Phase 4
13 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea Completed NCT01766206 Phase 4
14 Understanding the Immune Response to Two Different Meningitis Vaccines Completed NCT01593514 Phase 4
15 Can we Reduce the Number of Vaccine Injections for Children? Completed NCT01129518 Phase 4
16 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Completed NCT02633787 Phase 4
17 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
18 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
19 Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
20 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
21 Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children Completed NCT01430611 Phase 4
22 Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years Completed NCT00290329 Phase 4
23 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
24 Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage Completed NCT01119482 Phase 4
25 Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs Completed NCT00227422 Phase 4
26 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
27 Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time Completed NCT00581035 Phase 4
28 Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine Completed NCT00271479 Phase 4
29 Ciprofloxacin for the Prevention of Meningococcal Meningitis Completed NCT02724046 Phase 4 Ciprofloxacin
30 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
31 South Australian Meningococcal B Vaccine Herd Immunity Study Recruiting NCT03089086 Phase 4
32 Adolescent MenACWY Booster Study Recruiting NCT03694405 Phase 4
33 A Sourcing Study to Collect Human Blood Samples From Healthy Adults Recruiting NCT03493919 Phase 4
34 Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea Active, not recruiting NCT02864927 Phase 4
35 Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B Active, not recruiting NCT03125616 Phase 4
36 A Study to Evaluate Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction Enrolling by invitation NCT02868970 Phase 4
37 Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Not yet recruiting NCT03431675 Phase 4 Ciprofloxacin
38 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population Not yet recruiting NCT03682939 Phase 4
39 Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. Completed NCT02141516 Phase 3
40 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. Completed NCT01911221 Phase 3
41 Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects Completed NCT01641042 Phase 3
42 Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Completed NCT01682876 Phase 3
43 Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers Completed NCT01340898 Phase 3
44 Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers Completed NCT00626327 Phase 3
45 Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children Completed NCT00616421 Phase 3
46 Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children Completed NCT03476135 Phase 3
47 Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation Completed NCT01890759 Phase 3
48 A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India Completed NCT01086969 Phase 3
49 Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose Completed NCT01543087 Phase 3 bivalent rLP2086
50 Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations Completed NCT01359449 Phase 3

Search NIH Clinical Center for Meningococcal Infection

Genetic Tests for Meningococcal Infection

Anatomical Context for Meningococcal Infection

MalaCards organs/tissues related to Meningococcal Infection:

41
Brain, Testes, Spinal Cord, Spleen, B Cells, Kidney, Heart

Publications for Meningococcal Infection

Articles related to Meningococcal Infection:

(show top 50) (show all 386)
# Title Authors Year
1
Analysis of the impact of corticosteroids adjuvant treatment during experimental invasive meningococcal infection in mice. ( 29753775 )
2018
2
Lactobacillus paracasei feeding improves the control of secondary experimental meningococcal infection in flu-infected mice. ( 29636018 )
2018
3
50 Years Ago in TheJournal ofPediatrics: Factors in the Prognosis of Meningococcal Infection: Review of 63 Cases with Emphasis on Recognition and Management of the Severely Ill Patient. ( 26922764 )
2016
4
A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt. ( 26872255 )
2016
5
Self Mutilating Behaviour in Severe Meningococcal Infection; An Interesting Association. ( 27437275 )
2016
6
Meningitis with Digital Gangrene in Meningococcal Infection: An Atypical Presentation. ( 28208911 )
2016
7
Correction: A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt. ( 27379429 )
2016
8
Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations. ( 27449147 )
2016
9
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection. ( 25553243 )
2015
10
Relationships Between Clinico-Epidemiological Patterns of Invasive Meningococcal Infections and Complement Deficiencies in French South Pacific Islands (New Caledonia). ( 25352052 )
2015
11
The costs associated with the public health management of a cluster of meningococcal infection in England. ( 25173479 )
2014
12
Public health risk communication by text message in response to a cluster of invasive meningococcal infection in a primary school. ( 24894450 )
2014
13
Preventing meningococcal infections in India. ( 24986277 )
2014
14
Severe meningococcal infection: a review of epidemiology, diagnosis, and management. ( 23830646 )
2013
15
Patterns of meningococcal infection in Sudan with emergence of Neisseria meningitidis serogroup W135. ( 24313147 )
2013
16
Altered neutrophil counts at diagnosis of invasive meningococcal infection in children. ( 23736141 )
2013
17
Public health action and mass chemoprophylaxis in response to a small meningococcal infection outbreak at a nursery in the West Midlands, England. ( 23467531 )
2013
18
Pachymeningitis after meningococcal infection. ( 23642701 )
2013
19
Invasive meningococcal infection: analysis of 110 cases from a tertiary care centre in North East India. ( 22821284 )
2013
20
Management of a rifampicin-resistant meningococcal infection in a teenager. ( 23408002 )
2013
21
Genetic susceptibility to meningococcal infection. ( 23409824 )
2013
22
Corticosteroid therapy in genotype ST-11 meningococcal infections. ( 23114370 )
2013
23
Prevention of meningococcal infections in the first 2 years of life. ( 23910030 )
2013
24
Antibiotics for preventing meningococcal infections. ( 24163051 )
2013
25
Diagnosis of meningococcal infection by QPCR: detection and quantification of DNA / Neisseria meningitidis. ( 23272547 )
2012
26
Thyroid hormone enhances nitric oxide-mediated bacterial clearance and promotes survival after meningococcal infection. ( 22844479 )
2012
27
Classification and pathogenesis of meningococcal infections. ( 21993637 )
2012
28
Proficiency of PCR in hospital settings for nonculture diagnosis of invasive meningococcal infections. ( 22582511 )
2012
29
W135 invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012. ( 22687826 )
2012
30
A teenager with meningococcal infection. ( 21999443 )
2011
31
Real-time impedance analysis of host cell response to meningococcal infection. ( 21078346 )
2011
32
The burden of hospitalizations for meningococcal infection in Spain (1997-2008). ( 21664402 )
2011
33
Laboratory confirmed outbreak of meningococcal infections in Tripura. ( 21304204 )
2011
34
Antibiotics for preventing meningococcal infections. ( 21833949 )
2011
35
Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. ( 21946191 )
2011
36
Meningococcal infections in hospitalised patients in Pretoria. ( 22272863 )
2011
37
C7 deficiency and meningococcal infection susceptibility in two spanish families. ( 20591074 )
2010
38
Disseminated intravascular coagulation, meningococcal infection, and ischemic changes affecting the lower extremities: a case study. ( 20619693 )
2010
39
Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease. ( 19931914 )
2010
40
The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection. ( 20670394 )
2010
41
Can near real-time monitoring of emergency department diagnoses facilitate early response to sporadic meningococcal infection?--prospective and retrospective evaluations. ( 20979656 )
2010
42
Outbreak of Meningococcal Infection amongst Soldiers Deployed in Operations. ( 27365694 )
2010
43
Gram staining: an unexplored diagnostic tool for diagnosis of meningococcal infection in the developing world. ( 19176273 )
2009
44
Risk of transmitting meningococcal infection by transient contact on aircraft and other transport. ( 19296869 )
2009
45
Hospital admissions for meningococcal infection in Spain (1997-2005). ( 19042024 )
2009
46
MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. ( 20072946 )
2009
47
Review of meningococcal infection in children at a United Kingdom hospital. ( 19388559 )
2009
48
Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes. ( 19477561 )
2009
49
Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection. ( 21119789 )
2009
50
Susceptibility to meningococcal infection--nature versus nurture? ( 18779704 )
2008

Variations for Meningococcal Infection

Expression for Meningococcal Infection

Search GEO for disease gene expression data for Meningococcal Infection.

Pathways for Meningococcal Infection

GO Terms for Meningococcal Infection

Cellular components related to Meningococcal Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.17 AGT C7 CPB2 G6PD GSR SOD1

Biological processes related to Meningococcal Infection according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cellular response to oxidative stress GO:0034599 9.69 G6PD GSR SOD1
2 response to cold GO:0009409 9.63 ADRB1 ADRB2
3 activation of adenylate cyclase activity GO:0007190 9.62 ADRB1 ADRB2
4 positive regulation of reactive oxygen species metabolic process GO:2000379 9.62 AGT AGTR1
5 positive regulation of cytokine production GO:0001819 9.61 AGT SOD1
6 brown fat cell differentiation GO:0050873 9.61 ADRB1 ADRB2
7 regulation of vasoconstriction GO:0019229 9.6 AGT AGTR1
8 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.59 ADRB1 ADRB2
9 cellular sodium ion homeostasis GO:0006883 9.58 AGT C7
10 positive regulation of cellular protein metabolic process GO:0032270 9.58 AGT AGTR1
11 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.57 AGT AGTR1
12 positive regulation of superoxide anion generation GO:0032930 9.56 AGT SOD1
13 low-density lipoprotein particle remodeling GO:0034374 9.55 AGT AGTR1
14 regulation of blood vessel diameter GO:0097746 9.54 ADRB2 AGTR1
15 negative regulation of multicellular organism growth GO:0040015 9.52 ADRB1 ADRB2
16 glutathione metabolic process GO:0006749 9.5 G6PD GSR SOD1
17 positive regulation of cholesterol esterification GO:0010873 9.49 AGT AGTR1
18 diet induced thermogenesis GO:0002024 9.48 ADRB1 ADRB2
19 positive regulation of NAD(P)H oxidase activity GO:0033864 9.46 AGT AGTR1
20 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 AGT AGTR1
21 regulation of renal sodium excretion GO:0035813 9.4 AGT AGTR1
22 renin-angiotensin regulation of aldosterone production GO:0002018 9.37 AGT AGTR1
23 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.26 ADRB1 ADRB2
24 positive regulation of extracellular matrix constituent secretion GO:0003331 9.16 AGT CPB2
25 regulation of blood vessel diameter by renin-angiotensin GO:0002034 8.96 AGT AGTR1
26 heat generation GO:0031649 8.62 ADRB1 ADRB2

Molecular functions related to Meningococcal Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.56 ADD1 ADRB1 AGTR1 TTR
2 NADP binding GO:0050661 9.32 G6PD GSR
3 adrenergic receptor activity GO:0004935 9.16 ADRB1 ADRB2
4 epinephrine binding GO:0051379 8.96 ADRB1 ADRB2
5 norepinephrine binding GO:0051380 8.62 ADRB1 ADRB2

Sources for Meningococcal Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....